Income Statement
AEON BIOPHARMA, INC.
AEON
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Revenue
|
- | - | - | - | - |
|
Cost of Revenue
|
- | - | - | - | - |
|
Gross Profit
|
- | - | - | - | - |
|
Operating Expenses
|
12.80 | -72.99 | 0.00 | 3.33 | 1.94 |
|
Research & Development
|
4.09 | 14.18 | - | - | - |
|
Selling, General & Administrative
|
12.21 | 13.64 | - | - | - |
|
Other Operating Expenses
|
- | - | - | - | - |
|
Operating Income
|
-12.80 | 72.99 | - | -3.33 | -1.94 |
|
Non-Operating Income
|
-26.42 | -30.98 | - | 14.19 | 10.14 |
|
Interest Income
|
- | - | - | 3.71 | 0.08 |
|
Interest Expense
|
- | - | - | - | - |
|
Other Non-Op Income / Expense
|
0.29 | 0.10 | - | - | - |
|
Income Before Tax
|
-39.22 | 42.01 | - | 10.86 | - |
|
Income Tax Expense
|
0.00 | 0.00 | - | 0.88 | - |
|
Non-Controlling Interest
|
- | - | - | - | - |
|
Net Income
|
-39.22 | 42.01 | - | 9.98 | 8.20 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - |
|
EBITDA
|
-12.73 | 73.08 | 0.00 | -3.33 | -1.94 |
|
Earnings Per Share (Basic)
|
-3.95 | 77.74 | - | 0.29 | 0.26 |
|
Diluted EPS
|
-3.95 | 72.93 | - | 0.29 | 0.26 |
|
Weighted Average Shares
|
9.92 | 0.54 | - | 27.60 | 24.50 |
|
Diluted Weighted Avg Shares
|
9.92 | 0.58 | - | 27.60 | 24.50 |
|
Comprehensive Income
|
- | - | - | - | - |